"The voice for cancer physicians and their patients in Massachusetts."

FDA approves zanubrutinib for Waldenström’s macroglobulinemia

31 Aug 2021 3:22 PM | Katy Monaco (Administrator)
Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM).  Press ReleaseAugust 31, 2021.  More information.

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: msco@mms.org
Powered by Wild Apricot Membership Software